Naylor, G.J., et al
Together, you will discuss your expectations and design your treatment plan
10.1016/j.molmet.2018.09.009 [DOI] [PMC free article] [PubMed] [Google Scholar] Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, OFarrell LS, Briere DA, Sloop KW, Thomas MK, Pirro V, Wainscott DB, Willard FS, Abernathy M, Morford L, Du Y, Benson C, Gimeno RE, Haupt A, Milicevic Z (2022) LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept
MA: Formal analysis, Investigation, Methodology, Resources, Writing original draft, Writing review & editing
The company investigates and prosecutes counterfeit drug networks in collaboration with law enforcement agencies